MYD88 and neoplasm: UA activates the natural immune system through the TLR‐2‐myeloid differentiation primary response 88 (MyD88)–TRAF6 pathway, while PD‐L1 blockade promotes cytotoxic T cell infiltration, leading to significant tumor regression by simultaneously engaging innate and adaptive immunity [636].